Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Antibody-based therapy in Alzheimer’s disease: future outlook

Greg Lemke • 18 Mar 2022
AD/PD 2022
Alzheimer’s Disease Dementia Antibodies

Greg Lemke, PhD, Salk Institute for Biological Studies, San Diego, CA, discusses the importance and where we are concerning the progress in the field of Alzheimer’s disease therapies. Still in the early stages, there is much we do not know regarding antibody-based treatment against amyloid β, and further studies are needed to shed light on their mechanisms. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.

More from Greg Lemke

2:05
Developments on microglia in neuroinflammation: TREM2 upregulation in Alzheimer’s disease
Greg Lemke • 18 Mar 2022
2:32
Increasing the expression of Mer receptors in microglia: a potential therapy for Alzheimer’s disease
Greg Lemke • 18 Mar 2022
0:57
The function of TAM receptors in health and disease
Greg Lemke • 18 Mar 2022
3:25
Role of TAM receptors in Alzheimer’s disease
Greg Lemke • 18 Mar 2022

Related Videos

2:33
Anti-amyloid therapy for Alzheimer's disease: beyond the 18-month mark
Dorota Religa • 22 Mar 2024
0:50
Will long-term anti-amyloid treatment show greater clinical benefit?
Dorota Religa • 22 Mar 2024
1:24
Digital frailty screening in dementia
Dorota Religa • 22 Mar 2024
4:19
Current projects from Alzheimer’s Disease International
Paola Barbarino • 23 Mar 2024
The content of VJDementia is intended for healthcare professionals